LEADER 03007nam  2200433z- 450 
001 9910261144503321
005 20231214133321.0
035   $a(CKB)4100000002484647
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/42248
035   $a(EXLCZ)994100000002484647
100   $a20202102d2016      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aBiomarkers of Alzheimer's Disease: The Present and the Future
210   $cFrontiers Media SA$d2016
215   $a1 electronic resource (218 p.)
225 1 $aFrontiers Research Topics
311   $a2-88945-041-4 
330   $aAlzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders and loss of functional autonomy. AD represents the main cause of dementia and has become a major public health issue. In addition, the number of patients suffering from AD is growing rapidly as the population ages worldwide. Memory impairment is usually the earliest clinical and core symptom of this disease. The diagnosis at a late clinical stage is relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms of optimal medical and social care. The actual interest of the scientific head-ways is to optimize the diagnosis in prodromal stage of the disease and to propose personalized therapeutic solutions to individual patients. New revised AD diagnostic criteria include early alteration of cerebrospinal fluid (CSF) biomarkers: decrease of amyloïd peptides (Aß42), and increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of CSF biological biomarkers for the diagnosis of AD is a major step towards the ?molecular? diagnosis and follow-up of the disease. Many issues are however still subject of debate. This e-book provides a comprehensive overview of the state of the art of fluid biomarkers for AD, e.g. which novel biomarkers should be implemented in clinical practice for diagnosis or for monitoring treatment or side effects, which ones are new for AD or related dementias or what is the potential of peripheral blood markers. Moreover, the e-Book provides practical guidelines how to optimally and efficiently develop and validate novel biomarker assays, and to document and control pre-analytical variation.
517   $aBiomarkers of Alzheimer's Disease
610   $aValidation
610   $aNeurochemistry
610   $aDementias
610   $abiomarkers
610   $amethods
610   $adiscovery
610   $aCSF
610   $adiagnosis
610   $aAlzheimer
610   $aBlood
700   $aTeunissen$b Charlotte E$4auth$01371814
702   $aLehmann$b Sylvain$f1965-$4auth
906   $aBOOK
912   $a9910261144503321
996   $aBiomarkers of Alzheimer's Disease: The Present and the Future$93401455
997   $aUNINA